Qiagen (QGEN) Stock Price, News & Analysis

Company Overview

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing. QIAGEN also provides solutions for pharmaceutical research, biopharmaceutical development, academic research, food and animal testing, and forensic applications.

The company was founded in 1984 in Germany as Diagen and has since expanded into a multinational organization serving customers in North America, Europe, Asia and other international markets. QIAGEN is headquartered in Venlo, the Netherlands, with major operations in Germany and a global network of sales, manufacturing and research facilities. Thierry Bernard has served as chief executive officer since 2020.

Key Stats

• Today's Range: $43.49 to $43.91
• 50-Day Range: $40.50 to $44.86
• 52-Week Range: $32.53 to $57.81
• Volume: 89,660 shs
• Average Volume: 2.46 million shs
• Market Capitalization: $8.97 billion
• P/E Ratio: 22.30
• Dividend Yield: 0.80%
• Price Target: $43.51
• Consensus Rating: Hold

Qiagen Stock Analysis - MarketRank™

Qiagen scored higher than 77% of companies evaluated by MarketBeat, and ranked 132nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Qiagen has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 strong buy rating, 4 buy ratings, 9 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Qiagen is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Qiagen has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.41%

Earnings Growth

Earnings for Qiagen are expected to grow by 7.41% in the coming year, from $2.43 to $2.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Qiagen is 22.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qiagen is 22.32, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.54.

Price to Earnings Growth Ratio

Qiagen has a PEG Ratio of 4.46. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Qiagen has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.00% of the float of Qiagen has been sold short.

Short Interest Ratio / Days to Cover

Qiagen has a short interest ratio ("days to cover") of 2.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qiagen has recently decreased by 25.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Qiagen has a dividend yield of 0.78%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Qiagen does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Qiagen is 17.95%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Qiagen will have a dividend payout ratio of 13.41% next year. This indicates that Qiagen will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.62

News Sentiment

Qiagen has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Qiagen this week, compared to 5 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qiagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.00% of the stock of Qiagen is held by insiders.

Percentage Held by Institutions

70.00% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 7/14 Dividend: 7/07/2026
• Ex-Dividend for 7/14 Dividend: 7/07/2026
• Dividend Payable: 7/14/2026
• Last Earnings: 8/05/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:QGEN
• CIK: 1015820
• Web: www.qiagen.com
• Phone: (177) 355-6600
• Fax: 31-77-355-6658
• Employees: 5,654
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Qiagen: $43.51
• High Price Target: $50.00
• Low Price Target: $38.60
• Potential Upside/Downside: -0.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.95
• Trailing P/E Ratio: 22.37
• Forward P/E Ratio: 17.97
• P/E Growth: 4.46
• Net Income: $424.88 million
• Net Margins: 19.49%
• Pretax Margin: 21.99%
• Return on Equity: 14.47%
• Return on Assets: 8.34%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 2.85
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $2.09 billion
• Price / Sales: 4.30
• Cash Flow: $3.32 per share
• Price / Cash Flow: 13.15
• Book Value: $17.89 per share
• Price / Book: 2.44

Miscellaneous

• Outstanding Shares: 206,070,000
• Free Float: 187,528,000
• Market Cap: $9.00 billion
• Optionable: Optionable
• Beta: 0.63